Edward Mcgill, M.D.
NPI 1629033972 · Ophthalmology Physician · Omaha, NE
Enrolled with Medicare as Practitioner - Ophthalmology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1629033972
- Entity type
- Individual
- Primary specialty
- Ophthalmology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- No
- License
- 20457 (NE)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
6,190 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Imaging of Retina92134 | 2,594 | $37 |
| Injection of Drug Into Eye67028 | 1,180 | $109 |
| Established Patient Problem Focused Exam of Visual System92012 | 902 | $83 |
| Established Patient Complete Exam of Visual System92014 | 755 | $117 |
| New Patient Complete Exam of Visual System92004 | 223 | $138 |
| Unclassified BiologicsJ3590 | 213 | $87 |
| Photography of the Retina92250 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 12 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 488 | 110 |
| Dorzolamide Hcl/Timolol Maleatbrand: Dorzolamide-Timolol | 223 | 73 |
| Timolol Maleate | 196 | 39 |
| Neomycin/Polymyxin B/Dexamethabrand: Neomycin-Polymyxin-Dexameth | 125 | 93 |
| Prednisolone Acetate | 111 | 45 |
| Brimonidine Tartrate | 100 | 20 |
| Ketorolac Tromethamine | 57 | 22 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$139 across 1 record (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-04-19
- Last updated
- 2014-02-17
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.